whitepaper
Whitepaper: Addressing the challenges in biologics discovery with advanced flow cytometry
Biologics represent a growing class of drugs with indications in oncology, chronic inflammation, and autoimmune diseases.
List view / Grid view
Biologics
whitepaper
Application note: A kinase inhibitor phenotypic screen using a multiplex T Cell activation assay
Modulating the TCR signaling pathway using biologics, small molecules or genetic engineering is highly relevant to many therapeutic areas including cancer immunotherapy, adoptive cell therapy, vaccine development and autoimmune disease.
article
Expert view: High-throughput analytics for smarter cell-line development
Combine titer and glycan screening during clone selection and cell culture optimisation to make more informed choices sooner, significantly reducing the development time for therapeutic antibodies.
article
Intravenous immunoglobulins, hyperimmunes and pandemic viruses
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.
article
Rebalancing the immune system to treat autoimmune disease
Dr Nicolas Poirier reveals how immunotherapies can be designed to recalibrate the immune system for long-term maintenance of autoimmune remission.
news
Industry collaborate to screen existing drugs to repurpose for cystic fibrosis
In an effort to address some of the more serious untreatable infections encountered by patients with cystic fibrosis, Calibr will collaborate with the Cystic Fibrosis Foundation on a two-year project.
article
Getting precise: how humanised models aid in biologics drug discovery
Humanised immune system (HIS) models have enabled numerous in vivo evaluations of immuno-modulating biologic drugs and ongoing improvements continue to extend their utility. Paul Volden explores the application of HIS models in precision and personalised medicine with a focus on biologics, including how HIS models are used, why they are…
article
Bringing native analysis into the fast-moving world of biologics
For the past thirty years, native mass spectrometry has grown in both scope and reach in labs across the globe to encompass larger and more challenging molecular complexes. However, up until now, the throughput of these techniques has been slow and manual. Christopher Nortcliffe discusses ways that native analysis is…
article
Network-driven drug discovery
Target-driven drug discovery, in which the starting point is a specific protein target hypothesised to play an important role in disease, has been the dominant paradigm for the last few decades. However, phenotypic-driven drug discovery, which does not rely on a specific target hypothesis, is starting to regain traction for…
news
PD-L1 assay specifically selects ideal patients for cancer treatment
An assay assessing the level of programmed death ligand 1 (PD-L1) could help to determine the method of treatment for lung cancer patients...
news
Neurofilament light chains detect Alzheimer’s damage before symptoms
A simple blood test reliably detects signs of brain damage in people on the path to developing Alzheimer's disease...
news
Nanoscale ‘tweezers’ for individual cell biopsies
Researchers have developed nanoscale 'tweezers' used to investigate single living cells, which could help to identify why healthy cells become diseased...
whitepaper
Application note: Integrated biologics – Enabling high-throughput drug discovery at Amgen with Thermo Fisher™ Platform for Science™ Software
Every day scientists are working to discover and develop new therapies and treatments to change the lives of patients suffering from serious and debilitating illnesses. Amgen Inc. has made it a priority to unlock the potential of biology to discover, develop, manufacture, and deliver innovative therapeutics to patients.
news
Freeze-dried vaccine may help eradicate polio
Researchers have developed a polio vaccine that doesn't require refrigeration, meaning it could someday be used all over the world...